1. Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Chapter 46
Antineoplastic Drugs Part 2: Cell Cycle – Nonspecific Drugs and Miscellaneous Drugs
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

2. Cancer Drugs: Antineoplastic Medications
Cell cycle–nonspecific (CCNS) antineoplastic drugs
Alkylating drugs
Cytotoxic antibiotics
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

3. Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Alkylating Drugs
Classic alkylators (nitrogen mustards)
Nitrosoureas
Miscellaneous alkylators
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

4. Alkylating Drugs: Mechanism of Action
Work by preventing cancer cells from reproducing
Alter the chemical structure of the cells’ deoxyribonucleic acid (DNA)
Bifunctional or polyfunctional
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

5. Organization of DNA and Site of Action of Alkylating Drugs
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

6. Alkylating Drugs: Indications
Used in combination with other drugs to treat various types of cancer, such as:
Recurrent ovarian cancer
Brain tumors
Lymphomas
Leukemias
Breast cancer
Bladder cancer
Others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

7. Alkylating Drugs: Adverse Effects
Dose-limiting adverse effects
Nausea and vomiting, myelosuppression
Alopecia
Nephrotoxicity, peripheral neuropathy, ototoxicity
Hydration can prevent nephrotoxicity
Extravasation causes tissue damage and necrosis
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

8. Alkylating Drugs: Examples
cisplatin (Platinol)
cyclophosphamide (Cytoxan)
mechlorethamine (Mustine, nitrogen mustard)
carmustine (BiCNU)
Others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

9. Cytotoxic Antibiotics
Natural substances produced by the mold Streptomyces
Synthetic substances also used
Used to treat cancer; too toxic to treat infections
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

10. Cytotoxic Antibiotics (cont’d)
Anthracycline antibiotics
daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin
Other cytotoxic antibiotics
bleomycin, dactinomycin, mitomycin, mitoxantrone, plicamycin
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

11. Cytotoxic Antibiotics: Mechanism of Action
CCNS drugs are active in all phases of the cell cycle
Act by intercalation, resulting in blockade of DNA synthesis
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

12. Cytotoxic Antibiotics: Indications
Used in combination chemotherapy regimens
Used to treat a variety of solid tumors and some hematologic malignancies
Leukemia, ovarian, breast, bone, others
Squamous cell carcinomas
AIDS-related Kaposi’s sarcoma (when intolerant to other treatments)
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

13. Cytotoxic Antibiotics: Adverse Effects
All can produce bone marrow suppression, except bleomycin
Hair loss, nausea and vomiting, myelosuppression
Heart failure (daunorubicin)
Acute left ventricular failure (doxorubicin)
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

14. Cytotoxic Antibiotics: Adverse Effects (cont’d)
Pulmonary fibrosis and pneumonitis (bleomycin)
Liver, kidney, and cardiovascular toxicities
Many others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

15. Cytotoxic Antibiotics: Adverse Effects (cont’d)
Cardiomyopathy is associated with large amounts of doxorubicin
Routine monitoring of cardiac ejection fraction with multiple-gated acquisition (MUGA) scans
Cumulative dose limitations
Cytoprotective drugs such as dexrazoxane can decrease the incidence of this devastating toxicity
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

16. Classroom Response Question
Which cytotoxic antibiotic does the nurse identify as most likely to cause pulmonary fibrosis?
plicamycin
mitoxantrone
mitomycin
bleomycin
Correct answer: D
Rationale: Bleomycin is most likely to cause pulmonary fibrosis and pneumonitis. Plicamycin is most likely to cause tissue damage in the event of extravasation. Mitoxantrone is most likely to cause cardiovascular toxicity, and mitomycin is most likely to cause liver, kidney, and lung toxicities.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Elsevier items and derived items © 2009, 2005, 2001 by Saunders, an imprint of Elsevier Inc.

17. Miscellaneous Antineoplastics
bevacizumab (Avastin)
Angiogenesis inhibitor
Blocks blood supply to the growing tumor
Used to treat metastatic colon cancer, rectal cancer in combination with 5-fluorouracil, non–small cell lung cancer, and malignant glioblastoma
Many adverse effects, including nephrotoxicity
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

18. Classroom Response Question
Bevacizumab (Avastin) is an angiogenesis inhibitor. Which statement correctly describes the mechanism of action of an angiogenesis inhibitor?
It inhibits the formation of blood cells.
It inhibits the creation of new blood vessels in the tumor mass.
It interferes with the synthesis of DNA in the cancer tumor.
It causes cell death by inhibiting enzymes.
Correct answer: B
Rationale: Bevacizumab (Avastin) is the first approved angiogenesis inhibitor. Angiogenesis is the creation of new blood vessels that supply oxygen and other blood nutrients to growing tissues. In the case of malignant tumors, angiogenesis that occurs within the tumor mass promotes continued tumor growth. As a tumor enlarges, its central tissues gradually die off (necrosis). However, its outer portion continues to grow, often to fatal proportions, with blood supplied through angiogenesis. Thus, inhibiting this process offers a promising new mechanism for antineoplastic drug action.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Elsevier items and derived items © 2009, 2005, 2001 by Saunders, an imprint of Elsevier Inc.

19. Miscellaneous Antineoplastics (cont’d)
hydroxyurea (Hydrea, Droxia)
Action similar to antimetabolites
Used to treat squamous cell carcinoma and some leukemias
Many adverse effects (e.g., edema, drowsiness, headache, rash, hyperuricemia, nausea, vomiting, dysuria, myelosuppression, nephrotoxicity, pulmonary fibrosis)
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

20. Miscellaneous Antineoplastics (cont’d)
imatinib (Gleevec)
Used to treat chronic myeloid leukemia (CML)
Targeted therapy, but it is NOT a monoclonal antibody
Works by inhibiting an enzyme that is active in the CML process
Use with other hepatic-metabolized drugs may cause severe interactions
Many adverse effects and drug interactions
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

21. Miscellaneous Antineoplastics (cont’d)
mitotane (Lysodren)
Adrenal cytotoxic drug
Used specifically for inoperable adrenal corticoid carcinoma
Oral form only
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

22. Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Hormonal Drugs
Used to treat a variety of neoplasms in men and women
Hormonal therapy used to
Oppose effects of hormones
Block the body’s sex hormone receptors
Used most commonly as adjuvant and palliative therapy
But may be a drug of first choice for some cancers
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

23. Hormonal Drugs for Female-Specific Neoplasms
Aromatase inhibitors
anastrozole, aminoglutethimide
Selective estrogen receptor modulators
tamoxifen, toremifene
Progestins
megestrol (Megace), medroxyprogesterone
Androgens
fluoxymesterone, testolactone
Estrogen receptor antagonist
fulvestrant
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

24. Hormonal Drugs for Male-Specific Neoplasms
Antiandrogens
bicalutamide, flutamide, nilutamide
Gonadotropin-releasing hormone antagonists
leuprolide, goserelin
Antineoplastic hormone
estramustine
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

25. Radiopharmaceuticals and Antineoplastics
Porfimer sodium
Used to treat esophageal and bronchial tumors in combination with laser light therapy
Radiopharmaceuticals
Used to treat a variety of cancers, or symptoms caused by cancers
Administered by nuclear medicine specialists
samarium SM 153 lexidronam
sodium iodide I 131
sodium phosphate P 32
Others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

26. Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Extravasation
Leaking of an antineoplastic drug into surrounding tissues during IV administration
Can result in permanent damage to nerves, tendons, muscles; loss of limbs
Skin grafting or amputation may be necessary
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

27. Extravasation (cont’d)
Prevention is essential
Continuous monitoring of the IV site is essential
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

28. Extravasation (cont’d)
If suspected, stop the infusion immediately and contact the prescriber, but leave the intravenous catheter in place
Aspirate any residual drug and/or blood from the catheter
Consult guidelines or the pharmacist regarding antidotes, application of hot or cold packs and/or sterile occlusive dressings, and elevation and rest of the affected limb
Thoroughly document the extravasation incident
Consult facility protocol and guidelines
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

29. Classroom Response Question
When handling and administering vesicant drugs the nurse will:
double-flush the patient’s bodily secretions in the commode.
use sterile towels to clean up after chemotherapy spills.
mix chemotherapeutic drugs in the patient’s room.
teach the patient how to administer parenteral chemotherapeutic drugs.
Correct answer: A
Rationale: When providing care to patients receiving vesicant drugs as well as handling and administering these drugs the nurse should double-flush the patient’s bodily secretions in the commode and use special hampers for the disposal of all items that come in contact with the patient, including used personal protective equipment. If a spill should occur, the nurse should use special spill kits to clean up even the smallest chemotherapy spills. Nurses who are specially trained, current and certified should administer chemotherapeutic agents.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Elsevier items and derived items © 2009, 2005, 2001 by Saunders, an imprint of Elsevier Inc.

30. Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Nursing Implications
Assess baseline blood counts before administering antineoplastic drugs
Follow specific administration guidelines for each antineoplastic drug
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

31. Nursing Implications (cont’d)
Alkylating drugs
Monitor for expected effects of bone marrow suppression
Expect nausea, vomiting, diarrhea, stomatitis
Hydration is important to prevent nephrotoxicity
Report ringing/roaring in the ears—possible ototoxicity
Report tingling, numbness, or pain in extremities— peripheral neuropathies may occur
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

32. Nursing Implications (cont’d)
Cytotoxic antibiotics
Expect bone marrow suppression, nausea, vomiting, diarrhea, stomatitis
Monitor pulmonary status, since pulmonary fibrosis may occur
Monitor for nephrotoxicity, liver toxicity
Monitor cardiovascular status
Daunorubicin may turn the urine a reddish color
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

33. Nursing Implications (cont’d)
In general:
Monitor closely for anaphylactic reactions
Keep epinephrine, antihistamines, and antiinflammatory drugs on hand
Monitor closely for complications associated with bone marrow suppression
Anemia, thrombocytopenia, neutropenia
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

34. Nursing Implications (cont’d)
Cytoprotective drugs may be used to reduce toxicities
IV amifostine to reduce renal toxicity associated with cisplatin
IV or PO allopurinol to reduce hyperuricemia
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

35. Nursing Implications (cont’d)
Monitor for oncologic emergencies
Infections
Pulmonary toxicity
Allergic reactions
Stomatitis with severe ulcerations
Bleeding
Metabolic aberrations
Bowel irritability with diarrhea
Renal, liver, cardiac toxicity
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.